Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06869473 |
| Title | Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, As First-line Treatment for Recurrent/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients with a PD-L1 Combined Positive Score (CPS)>/=1=/<19. (AVEC-119) |
| Acronym | AVEC-119 |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | Gruppo Oncologico del Nord-Ovest |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | ITA |
CKB BOOST